Get started
Author

Lynn M. Flickinger

Recruitment strategies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial: The first six years
2000 · Nancy K. Simpson, Christine Cole Johnson, et al. · Controlled Clinical Trials · 57
Design and evolution of the data management systems in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial
2000 · Marsha A. Hasson, Richard M. Fagerstrom, et al. · Controlled Clinical Trials · 41
Examining the effects of false positive lung cancer screening results on subsequent lung cancer screening adherence.
2003 · Marvella E Ford, Suzanne L Havstad, et al. · PubMed · 37
Mammographic Breast Density Response to Aromatase Inhibition
2013 · Celine M. Vachon, Vera J. Suman, et al. · Clinical Cancer Research · 33
PDF
Randomized phase II trial of capecitabine and lapatinib with or without cixutumumab in patients with HER2+ breast cancer previously treated with trastuzumab and an anthracycline and/or a taxane: NCCTG N0733 (Alliance).
2014 · Paul Haluska, Albert M. Bernath, et al. · Journal of Clinical Oncology · 10
MC1923 phase II clinical trial of durvalumab (MEDI4736) and topotecan or lurbinectedin in patients with relapsed extensive-stage small cell lung cancer previously treated with chemotherapy and immunotherapy.
2022 · Konstantinos Leventakos, Anastasios Dimou, et al. · Journal of Clinical Oncology · 4
Quality of life (QOL) among patients (pts) with HER2+ breast cancer (bc) treated with adjuvant lapatinib and/or trastuzumab in the ALTTO study (BIG 2-06, Alliance N063D).
2014 · Amylou C. Dueck, David W. Hillman, et al. · Journal of Clinical Oncology · 4
Efficacy and safety study of neoadjuvant efineptakin alfa (NT-I7) and pembrolizumab in recurrent glioblastoma.
2023 · Mason Webb, Terry C Burns, et al. · Journal of Clinical Oncology · 3
Phase II clinical trial of PLX038 in patients with platinum resistant ovarian, primary peritoneal and fallopian tube cancer.
2024 · Andrea Elisabeth Wahner Hendrickson, Nathan R. Foster, et al. · Journal of Clinical Oncology · 1
PDF
CAST-AI: Cystectomy After Systemic Therapy With Antibody-Drug Conjugate and Immunotherapy
2026 · Jabra Zarka, Daniel S. Roberson, et al. · JCO oncology advances.
MC1923: Phase II durvalumab plus lurbinectedin in platinum-resistant relapsed extensive-stage small cell lung cancer after prior chemoimmunotherapy (cohort B).
2026 · Konstantinos Leventakos, Anastasios Dimou, et al. · Journal of Clinical Oncology
PDF
Protocol for Neuro-Oncology Anywhere: Deploying Mayo Clinic's remote cognitive assessment battery and wearable device monitoring platform while assessing the impact of metformin on cognition and quality of life in patients with history of cranial radiation
2026 · Ugur Sener, Bryan Neth, et al. · Contemporary Clinical Trials Communications
CAST-AI: Cystectomy after systemic therapy with ADC and immunotherapy.
2026 · Jabra Zarka, Elisabeth Bering, et al. · Journal of Clinical Oncology
PDF
NCOG-27. Neuro-oncology anywhere: A fully decentralized clinical trial evaluating cognitive assessments and interventions for patients who received intracranial radiation therapy
2025 · Ugur Sener, Bryan Neth, et al. · Neuro-Oncology
PDF
Neuro-oncology anywhere: Preliminary results from a decentralized clinical trial aimed at improving neurocognitive outcomes in patients with CNS malignancy.
2025 · Bryan Neth, Eva Alden, et al. · Journal of Clinical Oncology
Neuro-oncology anywhere: A decentralized approach to clinical trials in brain tumors and beyond.
2024 · Bryan Neth, Mason Webb, et al. · Journal of Clinical Oncology
Ctim-33. Efficacy and Safety Study of Neoadjuvant Efineptakin Alfa (nt-i7) and Pembrolizumab in Recurrent Glioblastoma
2023 · Mason Webb, Ugur Sener, et al. · Neuro-Oncology
PDF
CLO23-030: MC200402-Single-Arm Phase 2 Study of the FGFR Inhibitor Futibatinib (Futi) in Combination With Pembrolizumab (Pem) in Patients With FGF19 Expressing Advanced or Metastatic Hepatocellular Carcinoma (aHCC)
2023 · Nguyen H. Tran, Joseph J Larson, et al. · Journal of the National Comprehensive Cancer Network
Works count: 19
Citation count: 190
H-index: 5
I10-index: 5
Year
Topic
Type